塔西福林作为减肥治疗潜力:一项追溯纵向研究
Yorito Hattori1,2, Yuriko Nakaoku3, Soshiro Ogata3
1Department of Neurology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-shimmachi, Suita 564-8565, Osaka, Japan.
Nutrients
|February 26, 2025
概括
长期摄入taxifolin可能有助于减肥和肥胖管理. 这种天然的黄胺在一项临床研究中显示与减轻体重有显著的关联,没有任何不良事件.
科学领域:
- 营养保健品和食补充剂
- 肥胖研究的研究.
- 自然化合物的药理学.
背景情况:
- 目前的肥胖护理往往由于体重维持方面的挑战而长期失败.
- 需要新的,安全和可持续的肥胖药物.
- 在临床前研究中,Taxifolin是一种天然的黄类化合物,显示出保护作用并促进体重减轻.
研究的目的:
- 调查长期口服出租车folin摄入量和减肥之间的临床关联.
- 评估taxifolin用于肥胖管理的安全性和可持续性.
主要方法:
- 追溯纵向研究设计.
- 在接受300毫克/天taxifolin的患者中,与对照组对体重变化的比较.
- 在2021年1月至2021年7月期间的例行诊所访问中收集的数据.
主要成果:
- 总共分析了62名患者 (36名出租车folin,26名控制).
- 长期服用塔克西福林导致体重减轻显著增加 (-1.6公斤与-0.3公斤相比;p=0.026) 平均随访时间约为177天.
- 塔克西福林摄入量是增加体重减轻的独立预测因素 (调整后β-0.14;p=0.026) 没有观察到任何不良事件.
结论:
- 长期的每日口服taxifolin摄入似乎是预防或管理肥胖的一个安全和可持续的选择.
- 塔西福林显示出作为体重控制的新型治疗剂的潜力.
- 进一步的研究可能会验证taxifolin在临床肥胖治疗中的作用.
相关概念视频
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...